This trial will test whether a GLP-1 agonist or a dietary intervention can help girls with obesity and PCOS lower hepatic fat and improve insulin sensitivity.
1 Primary · 3 Secondary · Reporting Duration: Baseline and 12 weeks
50 Total Participants · 2 Treatment Groups
Primary Treatment: Semaglutide 3mg and 7mg [Rybelsus] · No Placebo Group · Phase 2 & 3
Age 12 - 21 · Female Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|University of Colorado Anshutz Medical Campus/Children's Hospital Colorado||100.0%|